Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (561-570 of 869) with videos related to

Pageof 87
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
A global expression-based analysis of the consequences of the t(4;14) translocation in myelomaAnn M Dring, Faith E Davies, James A L Fenton, et al.
British Journal of Haematology|April 3, 2015
Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantationMathew Weinstock, Yosra Aljawai, Elizabeth A Morgan, et al.
Cell Reports|December 28, 2018
Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple MyelomaMariateresa Fulciniti, Charles Y Lin, Mehmet K Samur, et al.
Blood|January 11, 2023
Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myelomaTing Du, Yan Song, Arghya Ray, et al.
Blood|May 19, 2007
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesisYu-Tzu Tai, Mariateresa Fulciniti, Teru Hideshima, et al.
Cancer Research|September 10, 2009
BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cellsMala Mani, Daniel E Carrasco, Yunyu Zhang, et al.
European Journal of Haematology|February 4, 2012
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomibPaul G Richardson, Jacob P Laubach, Robert L Schlossman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2020
Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome GroupMehmet Kemal Samur, Anil Aktas Samur, Mariateresa Fulciniti, et al.
American Journal of Hematology|July 24, 2010
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström MacroglobulinemiaIrene M Ghobrial, Wanling Xie, Swaminathan Padmanabhan, et al.
British Journal of Haematology|September 1, 2007
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cellsTeru Hideshima, Laurence Catley, Noopur Raje, et al.
Pageof 87

Showing results (561-570 of 869) with videos related to

Sort By:
Pageof 87
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
A global expression-based analysis of the consequences of the t(4;14) translocation in myelomaAnn M Dring, Faith E Davies, James A L Fenton, et al.
British Journal of Haematology|April 3, 2015
Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantationMathew Weinstock, Yosra Aljawai, Elizabeth A Morgan, et al.
Cell Reports|December 28, 2018
Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple MyelomaMariateresa Fulciniti, Charles Y Lin, Mehmet K Samur, et al.
Blood|January 11, 2023
Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myelomaTing Du, Yan Song, Arghya Ray, et al.
Blood|May 19, 2007
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesisYu-Tzu Tai, Mariateresa Fulciniti, Teru Hideshima, et al.
Cancer Research|September 10, 2009
BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cellsMala Mani, Daniel E Carrasco, Yunyu Zhang, et al.
European Journal of Haematology|February 4, 2012
The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomibPaul G Richardson, Jacob P Laubach, Robert L Schlossman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2020
Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome GroupMehmet Kemal Samur, Anil Aktas Samur, Mariateresa Fulciniti, et al.
American Journal of Hematology|July 24, 2010
Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström MacroglobulinemiaIrene M Ghobrial, Wanling Xie, Swaminathan Padmanabhan, et al.
British Journal of Haematology|September 1, 2007
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cellsTeru Hideshima, Laurence Catley, Noopur Raje, et al.
Pageof 87